Edgewise Therapeutics(EWTX) - 2025 Q3 - Quarterly Results

Exhibit 99.1 News Release Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. MESA open-label extension trial in adults with Becker: The Company continues to advance MESA, an open-label extension trial that collects long term safety and efficacy data of sevasemten t ...